CNR1 and obesity due to melanocortin 4 receptor deficiency: Theseresults highlight BNS808 as a promising candidate for obesity treatment.Additionally, our novel library of peripherally selective CB1R antagonists provides a strong foundation for future drug development.With further refinement, BNS808 holds significant clinical potentialto address the global obesity epidemic.